Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 6.66

Hangzhou Alltest Biotech Co., Ltd. Price to Sales Ratio (P/S) is 6.66 on January 14, 2025, a -3.74% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Hangzhou Alltest Biotech Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 7.95 on April 26, 2024, which is 19.31% above the current Price to Sales Ratio (P/S).
Hangzhou Alltest Biotech Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 4.83 on July 04, 2024, which is -27.48% below the current Price to Sales Ratio (P/S).
Hangzhou Alltest Biotech Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 6.36.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years